Polyethylene glycol modification of a galactosylated streptavidin clearing agent: Effects on immunogenicity and clearance of a biotinylated anti-tumour antibody

British Journal of Cancer

Volumn 73, Issue 5, 1996, Pages 565-572

  Marshall, D ^a   Pedley, R B ^a   Boden, J A ^a   Boden, R ^a   Melton, R G ^b   Begent, R H J ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Biotinylated anti tumour antibody; Galactosylated streptavidin; Immunogenicity; Polyethylene glycol

Indexed keywords

BIOTIN; CANCER ANTIBODY; CARCINOEMBRYONIC ANTIBODY; GALACTOSE; IODINE 125; MACROGOL; STREPTAVIDIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; INTRAPERITONEAL DRUG ADMINISTRATION; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; PLASMA CLEARANCE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

EID: 0030042161     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.99     Document Type: Article

References (48)

1. ABUCHOWSKI A, MCCOY JR, PALCZUK NC, VAN ES T AND DAVIS FF. (1977). Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem., 252, 3582-3586.
2. ABUCHOWSKI A, KAZO G, VERHOEST JR CR, VAN ES T, KAFKEWITZ D, NUCCI ML, VIAU AT AND DAVIS FF. (1984). Cancer therapy with chemically modified enzymes. I. Antitumour properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem. Biophys., 7, 175-186.
3. 2 derivative. J. Inorg. Biochem., 39, 149-159.
4. 2-macroglobulin. Anal. Biochem., 131, 25-33.
5. BEGENT RHJ, KEEP PA, GREEN AJ, SEARLE F, BAGSHAWE KD, JEWKES RF, JONES BE, BARRATT GM AND RYMAN BE. (1982). Liposomally entrapped second antibody improves tumour imaging with radiolabelled (first) antitumour antibody. Lancet, 2, 739-742.
6. DELGADO C, FRANCIS GE AND FISHER D. (1992). The uses and properties of PEG-linked proteins. Crit. Rev. Therap. Drug Carrier Syst., 9, 249-304.
7. DREBORG S AND AKERBLOM EB. (1990). Immunotherapy with monomethoxypolyethylene glycol modified allergens. Crit. Rev. Therap. Drug Carrier Syst., 6, 315-365.
8. DUBOIS M, GILLES KA, HAMILTON JK, REBERS PA AND SMITH F. (1956). Colorimetric method for determination of sugars and related substances. Anal. Chem., 28, 350-356.
9. FRAKER PJ AND SPECK JC. (1978). Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril. Biochem. Biophys. Res. Commun., 80, 849-857.
10. GREEN NM. (1965). A spectrophotometric assay for avidin and biotin based on binding of dyes by avidin. Biochem. J., 94, 23c-24c.
11. HALE G, DYER MJS, CLARK MR, PHILLIPS JM, MARCUS R, REICHMANN L, WINTER G AND WALDMANN H. (1988). Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet, 2, 1394-1399.
12. HIRD V, VERHOEYEN M, BADLEY RA, PRICE D, SNOOK D, KOSMAS C, GOODEN C, BAMIAS A, MEARES C, LAVENDER JP AND EPENETOS AA. (1991). Tumour localisation with a radioactively labelled reshaped human monoclonal antibody. Br. J. Cancer, 64, 911-914.
13. KAMISAKI Y, WADA H, YAGURA T, MATSUSHIMA A AND INADA Y. (1981). Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylenc glycol. J. Pharmacol. Exp. Ther., 216, 410-414.
14. KATRE NV. (1990). Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. Immunol. J., 144, 209-213.
15. KHAWLI LA, ALAUDDIN MM, MILLER GK AND EPSTEIN AL. (1993). Improved immunotargeting of tumors with biotinylated monoclonal antibodies and radiolabeled streptavidin. Antib. Immunoconj. Radiopharm., 6, 13-27.
16. KITAMURA K, TAKAHASHI T, YAMAGUCHI T, NOGUCHI A, NOGUCHI A, TAKASHINA K, TSURUMI H, INAGAKE M, TOYOKUNI T AND HAKOMORI S. (1991). Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy. Cancer Res., 51, 4310-4315.
17. LEAR JL, KASLIWAL RK, FEYERABEND AJ, PRATT JP, BUNN PA, DIENHART DG, GONZALEZ R, JOHNSON TK, BLOEDOW DC, MADDOCK SW AND GLENN SD. (1991). Improved tumor imaging with radiolabeled monoclonal antibodies by plasma clearance of unbound antibody with anti-antibody column. Radiology, 179, 509-512.
18. LEDERMANN JA, BEGENT RHJ, BAGSHAWE KD, RIGGS SJ, SEARLE F, GLASER MG, GREEN AJ AND DALE RG. (1988). Repeated antitumour antibody therapy in man with suppression of the host response by Cyclosporin A. Br. J. Cancer. 58, 654-657.
19. LEE WY AND SEHON AH. (1977). Abrogation of reaginic antibodies with modified allergens. Nature, 267, 618-619.
20. LoBUGLIO AF, WHEELER RH, TRANG J, HAYNES A, ROGERS K, HARVEY EB, SUN L, GHRAYEB J AND KHAZAELI MB. (1989). Mouse human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl Acad. Sci. USA., 86, 4220-4224.
21. LYONS A, KING DJ, OWENS RJ, YARRANTON GT, MILLICAN A, WHITTLE NR AND ADAIR JR. (1990). Site-specific attachment to recombinant antibodies via introduced surface cysteine residues. Protein Eng., 3, 703-708.
22. MARSHALL D, PEDLEY RB, BODEN JA, BODEN R AND BEGENT RHJ. (1994). Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model. Br. J. Cancer, 69, 502-507.
23. 2 fragments of an anti-tumour antibody. Br. J. Cancer. 71, 18-24.
24. NORRGREN K, STRAND S-E, NILSSON R, LINDGREN L AND SJOGREN H-O. (1993). A general, extracorporeal immunosorption method to increase the tumor to normal tissue ratio in radioimmunoimaging and radioimmunotherapy. J. Nucl. Med., 34, 448-454.
25. PAGANELLI G, STELLA M, DE NARDI P, MAGNANI P, ZITO K, SICCARDI AG, DI CARLO V AND FAZIO F. (1990a). A new method for faster blood clearance in radioimmuno-guided surgery. J. Nucl. Med. Allied Sci., 35, 88-89.
26. PAGANELLI G, PERVEZ S, SICCARDI AG, ROWLINSON G, DELEIDE G, CHIOLERIO I, MALCOVATI M, SCASSELLATI GG AND EPENETOS AA. (1990B). Intraperitoneal radio-localistion of tumours pre-targeted by biotinylated monoclonal antibodies. Int. J. Cancer. 45, 1184-1189.
27. PAGANELLI G, MAGNANI P, ZITO F, VILLA E, SUDATI F, LOPALCO L, ROSSETI L, MALCOVATI M, CHIOLERIO F, SECCAMANI E, SICCARDI AG AND FAZIO F. (1991a). Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res., 51, 5960-5966.
28. PAGANELLI G, MALCOVATI M AND FAZIO F. (1991b). Monoclonal antibody pretargeting techniques for tumour localization: the avidin-biotin system. Nucl. Med. Commun., 12, 211-234.
29. PAGANELLI G, BELLONI C, MAGNANI P, ZITO F, PASINI A, SASSI I, MERONI M, MARIANI M, VIGNALI M, SICCARDI AG AND FAZIO F. (1992). Two-step tumour targeting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin. Eur. J. Nucl. Med., 19, 322-329.
30. PEDLEY RB, BODEN J, KEEP PA, HARWOOD PJ, GREEN AJ AND ROGERS GT. (1987). Relationship between tumour size and uptake of radiolabelled anti-CEA in a colonic tumour xenograft. Eur. J. Nucl. Med., 13, 197-202.
31. PEDLEY RB, DALE R, BODEN JA, BEGENT RHJ, KEEP PA AND GREEN AJ. (1989). The effect of second antibody clearance on the distribution and dosimetry of radiolabelled anti-CEA antibody in a human colonic tumour xenograft model. Int. J. Cancer, 43, 713-718.
32. PEDLEY RB, BODEN J, BODEN R, BEGENT RHJ, TURNER A, HAINES AMR AND KING DJ. (1994). The potential for enhanced tumour localistion by poly(ethylene glycoL) modification of anti-CEA antibody. Br. J. Cancer, 70, 1126-1130.
33. PRESS OW, EARY JF, APPELBAUM FR, MARTIN PJ, BADGER CC, NELP WB, GLENN S, BUTCHKO G, FISHER D, PORTER B, MATTHEWS DC, FISHER LD AND BERNSTEIN ID. (1993). Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med., 329, 1219-1224.
34. SAGA T, WEINSTEIN JN, JEONG JM, HEYA T, LEE JT, LE N, PAIK CH, SUNG C AND NEUMANN RD. (1994). Two-step pretargeting of experimental lung metastases with biotinylated antibody and radiolabeled streptavidin. Cancer Res., 54, 2160-2165.
35. SAVOCA KV, DAVIS FF AND PALCZUK NC. (1984). Induction of tolerance in mice by uricase and monomethoxypolyethylene glycol-modilied uricase. Int. Arch. Allergy Appl. Immun., 75, 58-67.
36. SHARKEY RM, MABUS J AND GOLDENBERG DM. (1988). Factors influencing anti-antibody enhancement of tumor targeting with antibodies in hamsters with human colonic tumor xenografts. Cancer Res., 48, 2005-2009.
37. SHARKEY RM, BOERMAN OC, NATALE A, PAWLYK D, MONESTIER M, LOSMAN MJ AND GOLDENBERG DM. ( 1992). Enhanced clearance of radiolabeled murine monoclonal antibody by a syngeneic anti-idiotype antibody in tumor-bearing nude mice. Int. J. Cancer, 51, 266-273.
38. SINITSYN VV, MAMONTOVA AG, CHECKNEVA YY, SHNYRA AA AND DOMOGATSKY SP. (1989). Rapid blood clearance of biotinylated IgG after infusion of avidin. J. Nucl. Med., 30, 66-69.
39. SUZUKI T, KANBARA N, TOMONO T, HAYASHI N AND SHINOHARA I. (1984). Physicochemical and biological properties of poly(ethylene glycol)-coupled immunoglobulin G. Biochim. Biophys. Acta, 788, 248-255.
40. TOM BH, RUTZKY LP, JAKSTYS MM, OYASU R, KAYE CI AND KAHAN BD. (1976). Human colonic adenocarcinoma cells. In Vitro, 12, 180-191.
41. TSUTSUMI Y, KIHIRA T, TSUNODA S, KANAMORI T, NAKAGAWA S AND MAYUMI T. (1995). Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency. Br. J. Cancer, 71, 963-968.
42. TURNER A, KING DJ, FARNSWORTH APH, RHIND SK, PEDLEY RB, BODEN J, BODEN R, MILLICAN TA, MILLAR K, BOYCE B, BEELEY NRA, EATON MAW AND PARKER D. (1994). Comparative biodistributions of indium-111-labelled macrocycle chimeric B72.3 antibody conjugates in tumour-bearing mice. Br. J. Cancer. 70, 35-41.
43. VERONESE FM. (1994). Enzyme surface modification by polymers for improved delivery. J. Control. Release, 29, 171-176.
44. WIEDER KJ, PALCZUK NC, VAN EST AND DAVIS FF. (1979). Some properties of polyethylene glycol:phenylalanine ammonia-lyase adducts. J. Biol. Chem., 254, 12579-12587.
45. WILCHEK M AND BAYER EA. (1989). Avidin-biotin technology ten years on: has it lived up to its expectations? Trends Biol. Sci., 14, 408-413.
46. WILKINSON I, JACKSON C-JC, LANG GM, HOLFORD-STREVENS V AND SEHON AH. (1987a). Tolerogenic polyethylene glycol derivatives of xenogeneic monoclonal immunoglobulins. Immunol. Lett., 15, 17-22.
47. WILKINSON I, JACKSON C-JC, LANG GM, HOLFORD-STREVENS V AND SEHON AH. (1987b). Tolerance induction in mice by conjugates of monoclonal immunoglobulins and monomethoxypolyethylene glycol. Transfer of tolerance by T cells and by T cell extracts. J. Immunol., 139, 326-331.
48. YOSHINAGA K, SHAFER SG AND HARRIS JM. (1987). Effects of polyethylene glycol substitution on enzyme activity. J. Bioact. Compat. Polym., 2, 49-56.